target audience: TECH BUYER  Publication date: Sep 2022 - Document type: IDC MarketScape - Doc  Document number: # US49648822

IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial Consulting Services 2022 Vendor Assessment

By:  Nimita Limaye Loading

Content



Get More

When you purchase this document, the purchase price can be applied to the cost of an annual subscription, giving you access to more research for your investment.



Related Links

Abstract


This IDC study is the first of a two-part IDC MarketScape series for life science R&D. With a specific focus on strategic consulting in the life science R&D DCT space, this document is a qualitative and quantitative assessment based on criteria that should be important to life science companies when considering the selection of a strategic DCT consulting partner to help provide guidance for strategic, operational, and tactical transformation issues within the DCT space. This is the first time that an IDC MarketScape assessment of DCT consulting services in life science R&D has been performed.

Dr. Nimita Limaye, research VP, Life Science R&D Strategy and Technology at IDC, noted, "The DCT space is a turbulent and an evolving one. The COVID-19 pandemic accelerated the adoption of DCTs, challenging cynics who opined that DCTs would never happen. However, the industry is still testing the waters, and there is still a long, long way to go. The tangibles, such as defining KPIs and KRIs for DCT implementation, and assessing return on investment, are not yet in place. Organizations are still building their playbook for DCT implementation at scale, and DCT consulting partners that can help define that strategic road map and build out a robust, repeatable implementation strategy, with plug-and-play models based on phase, therapeutic area, and geography, to accelerate time to market, will be the unquestioned leaders."



Coverage


Do you have questions about this document
or available subscriptions?